Biomea Fusion Inc Dossier - Source-backed chat

Biomea Fusion Inc

BMEANASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.00

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $1.30Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $94M

Enterprise Value $48.9M

Shares Outstanding 72.3M diluted

Next Earnings Date31 Dec 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Biomea Fusion is a clinical-stage biopharmaceutical company that has successfully transitioned from a period of regulatory and leadership turbulence to a highly focused developer of novel oral small molecules for diabetes and obesity. Following the resolution of the FDA clinical hold on its lead candidate icovamenib (BMF-219) in late 2024 and a strategic restructuring in early 2025, the company is poised to deliver major clinical catalysts in the second half of 2026. With a lean operating structure, strong insider alignment, and a cash runway extending into Q1 2027, Biomea represents a high-upside opportunity in the massive metabolic disease market.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets6 analysts · as of 18 Aug 2026

Low · most bearish analyst$4.00

Mean target$6.83

High · most bullish analyst$9.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$3.0020%

Icovamenib's Phase II readouts show marginal efficacy or a recurrence of liver safety signals under the revised dosing protocol, or BMF-650 fails to show meaningful weight loss. The company faces severe dilution risks as its cash runway approaches Q1 2027 without a partner.

Base CaseCentral scenario

$6.8350%

Matches the consensus mean

Phase II trials for icovamenib meet their primary endpoints with a clean safety profile, confirming the drug's unique disease-modifying mechanism of action. BMF-650 establishes proof-of-concept as an oral GLP-1 receptor agonist. The company secures additional financing or a development partnership to extend its runway into Phase III.

Bull CaseUpside scenario

$12.0030%

Icovamenib demonstrates superior, durable glycemic control in insulin-deficient Type 2 Diabetes patients and those failing GLP-1 therapies, while BMF-650's Phase I data shows competitive oral weight-loss efficacy. This triggers lucrative regional licensing deals in high-prevalence markets (e.g., China, India) and a major upward re-rating of the stock.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

First-in-class covalent menin inhibitor (icovamenib) targeting beta-cell regeneration, offering potential disease-modifying therapy rather than chronic symptom management.
Strong clinical data showing durable glycemic improvements persisting months after treatment discontinuation.
Highly aligned management team with significant insider ownership and recent open-market stock purchases.
Diversified metabolic pipeline including BMF-650, an oral next-generation GLP-1 receptor agonist.

Key Investment Risks

Clinical-stage risk with no commercial revenues and high cash burn rate.
Historical regulatory volatility, including a prior FDA clinical hold due to hepatotoxicity concerns.
Intense competition in the diabetes and obesity space from established pharmaceutical giants.
Limited cash runway projected into Q1 2027, necessitating near-term capital raises.

Thesis Invalidation Triggers

Failure of icovamenib to meet primary HbA1c endpoints in COVALENT-211 or COVALENT-212.
Re-imposition of an FDA clinical hold due to safety or liver toxicity signals.
Inability to secure non-dilutive funding or strategic partnerships before Q4 2026.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.